BioSpace News Archive

Elekta announced that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510 clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherapy techniques.

Mind Cure Health Inc., a leader in advanced proprietary technology and research for psychedelics, is pleased to announce it has developed two proprietary ketamine-enhanced protocols for psychedelic-assisted psychotherapy – one for treating pain and another for treating depression.

Twelve Bio, a gene-editing company pioneering the therapeutic application of CRISPR-Cas12 medicines, announced the appointment of Gita Dittmar, DVM, as independent Executive Chairman of the company’s Board of Directors.

Sparta Science has partnered with the University of Southern California’s Center for Body Computing to conduct a series of iterative research studies aimed at understanding how to best utilize force plates and machine learning algorithms to predict risk for and mitigate musculoskeletal injuries within U.S. military servicemembers.

Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the addition of Jacques Mizrahi, Ph.D., to its scientific advisory board.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory Board.

Data from AMF’s American Registry for Migraine Research informed a study looking at headache days and disability.

The U.S. Food and Drug Administration Center for Biologics Evaluation and Research has granted approval to Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.

OncoNano Medicine, Inc. announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross border institutional investment fund.

Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, announced it has received a $3 million award from Advanced Technology International to support the company’s Phase 1 study of PNT001 in hospitalized patients with acute traumatic brain injury.